# Prime Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prime-medicine

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.primemedicine.com
- Total disclosed funding: $315M
- Latest round: Series B (Jul 13, 2021)
- Investors on record: 12

## About

Founded in 2019 and based in Massachusetts, US, Prime Medicine, Inc. operates as a developer of novel gene-editing technology solutions that can cure and prevent genetic diseases. The company was co-founded by David R. Liu, Ph.D., and Andrew Anzalone, MD, Ph.D. In May 2024, Alphabet, a portfolio company of The Google LLC, acquired Prime Medicine Inc. As of 2025 the company is headed by its CEO Allan Reine.

The company offers a next-generation technology called Prime Editing, that can search and replace to restore normal gene function and address the fundamental causes of disease and treat diseases that benefit patients.

## Funding rounds

- Series B, Jul 13, 2021, $200M — ARCH Venture Partners, T Rowe Price, Public Sector Pension Investment Board, GV, Redmile Group, Casdin Capital, Cormorant Asset Management, Samsara BioCapital, Moore Strategic Ventures, Newpath Partners
- Series A, Oct 22, 2019, $115M — ARCH Venture Partners, F-Prime Capital, GV, Arrive, Newpath Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Arrive (https://capitalatlas.ai/funds/arrive) — Series A
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Public Sector Pension Investment Board — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series B